Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Study of JNJ-67856633 in B-cell NHL and CLL
jRCT2041200066Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of JNJ-67856633 in mature B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity (DLT) in Part 1 and Number of Participants with Adverse Events (AEs). Started Mar 2021; status: completed.
02
Drugs
JNJ-67856633
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2041200066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200066.